Literature DB >> 3498618

Gastrointestinal side effects with erythromycin preparations.

B L Carter1, J C Woodhead, K J Cole, G Milavetz.   

Abstract

This study was designed to determine the incidence and severity of gastrointestinal (GI) side effects in patients taking erythromycin. More patients complained of GI side effects with the enteric-coated tablet (70.8 percent) than with the stearate (51.4 percent) or the ethylsuccinate (48.9 percent) salts. The enteric-coated tablet was associated with a higher incidence of individual adverse reactions; more patients discontinued it because of adverse GI effects. These data demonstrate a high incidence of GI side effects to erythromycin. Additionally, GI side-effect incidence appears to be higher with the enteric-coated tablet.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3498618     DOI: 10.1177/106002808702100914

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  4 in total

1.  Effect of erythromycin on the oro-caecal transit time in man.

Authors:  J Lehtola; P Jauhonen; A Kesäniemi; R Wikberg; A Gordin
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  Pharmacologic Management of Mycobacterium chimaera Infections: A Primer for Clinicians.

Authors:  Matt Mason; Eric Gregory; Keith Foster; Megan Klatt; Sara Zoubek; Albert J Eid
Journal:  Open Forum Infect Dis       Date:  2022-06-15       Impact factor: 4.423

3.  Bioavailability and stability of erythromycin delayed release tablets.

Authors:  S Ogwal; T U Xide
Journal:  Afr Health Sci       Date:  2001-12       Impact factor: 0.927

4.  Comparative study of clarithromycin and penicillin V in the treatment of streptococcal pharyngitis.

Authors:  G E Stein; S Christensen; N Mummaw
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-11       Impact factor: 3.267

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.